skeletal-related event

skeletal-related event

The metastasis of a tumor to bone, and/or its clinical effects.
Mentioned in ?
References in periodicals archive ?
In the '482 study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.
Kaplan-Meier curves of time from PC index date to first skeletal-related event by type of event in patients with metastatic bone disease.
In the evaluation of the effectiveness of current pharma-cotherapy, a skeletal-related event (SRE) has been defined as an event involving fracture, orthopaedic intervention, radiation therapy, or spinal cord compression.
Patients treated with denosumab experienced a similar time to first skeletal-related event (SRE), defined as fracture, radiation to bone, surgery to bone, or spinal cord compression, compared with those receiving Novartis AG's Zometa, which was the main goal of the non-inferiority study.
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.
The study met the primary endpoint, demonstrating non-inferiority of XGEVA to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma.
Each skeletal-related event is estimated to cost an average of $7,553 per radiation episode to $88,838 per bone surgery episode (Yong, Onukwugha, & Mullins, 2014), and are often recurring events throughout the course of malignant disease (Hatoum, Lin, Smith.
This analysis demonstrated an improved delay in time to first skeletal-related event for the XGEVA treated patients.
The primary endpoint was a non-inferiority test defined by the time to the first skeletal-related event.
Key Words: Bone metastases, cancer-induced bone disease, cancer therapy induced bone loss, skeletal-related event (SRE), bisphosphonates, RANK ligand inhibitors, zoledronic acid, denosumab, hypocalcemia, osteonecrosis of the jaw, skeletal health.
The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.